Ixabepilone and lapatinib for HER2-positive advanced breast cancer: Preclinical rationale and phase I trial

Citation

• Mainwaring, P. N., Nguyen, T., Price, G., & Venter, D. (2009). Ixabepilone and lapatinib for HER2-positive advanced breast cancer: Preclinical rationale and phase I trial. Journal of Clinical Oncology, 27(15_suppl), 2582. doi:10.1200/jco.2009.27.15_suppl.2582

Digital Object Identifier (doi)

• 10.1200/jco.2009.27.15_suppl.2582

Web Of Science Accession Number

Start Page

• 2582

End Page

• 2582

Volume

• 27

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   Venter, Deon (external author)

Publication Date

• 2009

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Mainwaring, P. N., Nguyen, T., Price, G., & Venter, D. (2009). Ixabepilone and lapatinib for HER2-positive advanced breast cancer: Preclinical rationale and phase I trial. Journal of Clinical Oncology, 27(15_suppl), 2582. doi:10.1200/jco.2009.27.15_suppl.2582

Digital Object Identifier (doi)

• 10.1200/jco.2009.27.15_suppl.2582

Web Of Science Accession Number

Start Page

• 2582

End Page

• 2582

Volume

• 27

Issue

• 15_suppl

Place Of Publication